Pharmacogenomics: The importance of accurate phenotypes

Pharmacogenomics

Volumn 11, Issue 4, 2010, Pages 469-470

  Gurwitz, David ^a   Pirmohamed, Munir ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adverse drug reactions; Biobanks; Drug efficacy; Drug response phenotype; Electronic health records; Epigenomics; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ACCURACY; DRUG RESPONSE; EPIGENETICS; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; PHARMACOGENOMICS; PHENOTYPE; PUBLICATION; REVIEW;

DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENESIS, GENETIC; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHENOTYPE;

EID: 77950346153     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.41     Document Type: Review

References (14)

1. Need AC, Motulsky AG, Goldstein DB: Priorities and standards in pharmacogenetic research. Nat Genet. 37(7), 671-681 (2005).
2. Giacomini KM, Krauss RM, Roden DM et al.: When good drugs go bad. Nature 2446(7139), 975-977 (2007).
3. Woodcock J, Lesko LJ: Pharmacogenetics-tailoring treatment for the outliers. N. Engl. J. Med. 360(8), 811-813 (2009).
4. Pirmohamed M: The applications of pharmacogenetics to prescribing: what is currently practicable? Clin Med. 9(5), 493-495 (2009).
5. Gurwitz D, Zika E, Hopkins MM, Gaisser S, Ibarreta D: Pharmacogenetics in Europe: barriers and opportunities. Public Health Genomics 12(3), 134-141 (2009).
6. Ikediobi ON, Shin J, Nussbaum RL et al.: Addressing the challenges of the clinical application of pharmacogenetic testing. Clin. Pharmacol. Ther. 86(1), 28-31 (2009).
7. Holmes MV, Shah T, Vickery C et al.: Fulflling the promise of personalized medicine? Systematic review and feld synopsis of pharmacogenetic studies. PLoS One 4(12), E7960 (2009).
8. Ng PC, Murray SS, Levy S, Venter JC: An agenda for personalized medicine. Nature 461(7265), 724-726 (2009).
9. Daly AK, Donaldson P T, Bhatnagar P et al.: HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to fucloxacillin. Nat. Genet. 41(7), 816-819 (2009).
10. Ge D, Fellay J, Thompson AJ et al.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
11. Chung CM, Wang RY, Chen JW et al.: A genome-wide association study identifes new loci for ACE activity: potential implications for response to ACE inhibitor. Pharmacogenomics J. (2010) (Epub ahead of print).
12. Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B: Genome-wide association study of antipsychotic-induced Parkinsonism severity among schizophrenia patients. Psychopharmacology (Berl.) 206(3), 491-499 (2009).
13. Samuels DC, Burn DJ, Chinnery PF: Detecting new neurodegenerative disease genes: does phenotype accuracy limit the horizon? Trends Genet. 25(11), 486-488 (2009).
14. Lunshof JE, Pirmohamed M, Gurwitz D: Personalized medicine: decades away? Pharmacogenomics 7(2), 237-241 (2006).